HYDERABAD/BENGALURU (Reuters) – Cipla, India’s third-largest generics drugmaker by sales, posted first-quarter profit above expectations on Friday, aided by higher sales in its North America and domestic markets.
The company reported an 18.3% rise in consolidated net profit to 11.78 billion rupees ($140.8 million) for the quarter ended June 30, beating analysts’ estimate of 11.10 billion rupees, as per LSEG data.
($1 = 83.6950 Indian rupees)
(Reporting by Rishika Sadam and Kashish Tandon in Bengaluru; Editing by Sonia Cheema)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.